Drs. Bernard Thébaud, Yan Xu and Vignan Yogendrakumar The federal government announced a new round of Canada Research Chairs this week, including three based at The Ottawa Hospital. 

Dr. Bernard Thébaud, neonatologist and senior scientist in OHRI’s Regenerative Medicine Program, was appointed Tier 1 Canada Research Chair in Lung Stem Cell Biology and Regeneration. Dr. Thébaud’s team, which is also affiliated with CHEO Research Institute, is focused on translating innovative cell and gene therapy research into new treatments for premature babies. 

Dr. Yan Xu, hematologist and associate scientist in OHRI’s Acute Care Research Program, was appointed Tier 2 Canada Research Chair in Thrombosis. Dr. Xu’s research aims to aims to better understand blood clots in racialized populations, so that prevention, diagnosis and treatment decisions are based on data that reflect Canada’s diverse population. 

Dr. Vignan Yogendrakumar, neurologist and associate scientist in OHRI’s Neuroscience Program, was appointed Tier 2 Canada Research Chair in Stroke. Dr. Yogendrakumar’s research aims to optimize the use of clot-busting drugs for stroke treatment and evaluate next-generation therapies. These three chairs are among 15 new and renewed Canada Research Chairs awarded to uOttawa-affiliated researchers.

The Ottawa Hospital is a leading academic health, research and learning hospital proudly affiliated with the University of Ottawa and supported by The Ottawa Hospital Foundation.